Wipfli Financial Advisors LLC Buys Shares of 1,519 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Wipfli Financial Advisors LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,519 shares of the biopharmaceutical company’s stock, valued at approximately $60,000.

A number of other institutional investors also recently modified their holdings of HALO. Meritage Portfolio Management acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at $8,089,000. Raymond James & Associates lifted its stake in shares of Halozyme Therapeutics by 79.5% in the 3rd quarter. Raymond James & Associates now owns 74,854 shares of the biopharmaceutical company’s stock valued at $2,960,000 after purchasing an additional 33,149 shares during the last quarter. Mizuho Markets Americas LLC acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at $14,184,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at $986,000. Finally, Louisiana State Employees Retirement System acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at $1,451,000. Institutional investors and hedge funds own 96.32% of the company’s stock.

Halozyme Therapeutics Stock Down 0.7 %

NASDAQ HALO opened at $50.34 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $31.36 and a twelve month high of $59.46. The company has a debt-to-equity ratio of 15.37, a quick ratio of 5.03 and a current ratio of 5.97. The stock has a market cap of $6.81 billion, a PE ratio of 33.79, a PEG ratio of 0.63 and a beta of 1.23. The firm has a 50-day simple moving average of $55.16 and a 200 day simple moving average of $48.09.

Halozyme Therapeutics (NASDAQ:HALOGet Rating) last announced its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.21. The company had revenue of $208.98 million during the quarter, compared to the consensus estimate of $187.87 million. Halozyme Therapeutics had a return on equity of 134.71% and a net margin of 36.37%. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 2.07 EPS for the current year.

Insider Buying and Selling

In related news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $52.15, for a total value of $521,500.00. Following the completion of the transaction, the chief executive officer now directly owns 587,177 shares of the company’s stock, valued at $30,621,280.55. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CFO Nicole Labrosse sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $53.81, for a total value of $269,050.00. Following the completion of the transaction, the chief financial officer now directly owns 4,045 shares of the company’s stock, valued at $217,661.45. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $52.15, for a total value of $521,500.00. Following the completion of the transaction, the chief executive officer now directly owns 587,177 shares of the company’s stock, valued at $30,621,280.55. The disclosure for this sale can be found here. Insiders sold a total of 65,000 shares of company stock valued at $3,637,650 over the last ninety days. 2.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. SVB Leerink reduced their price objective on shares of Halozyme Therapeutics from $62.00 to $61.00 and set an “outperform” rating for the company in a research note on Wednesday. Morgan Stanley lifted their price objective on shares of Halozyme Therapeutics from $53.00 to $65.00 and gave the company an “overweight” rating in a research note on Wednesday, December 21st. StockNews.com assumed coverage on shares of Halozyme Therapeutics in a research report on Wednesday, October 12th. They set a “hold” rating for the company. JPMorgan Chase & Co. boosted their target price on shares of Halozyme Therapeutics from $53.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 22nd. Finally, JMP Securities boosted their target price on shares of Halozyme Therapeutics from $60.00 to $62.00 and gave the stock a “market outperform” rating in a research report on Wednesday, November 9th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $59.63.

Halozyme Therapeutics Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Stories

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.